Middle East Pharmaceutical Industries Company

4016.SRSAUHealthcare● Active

$62.10

$-0.20(-0.32%)

Market Cap$2.2B

P/E Ratio—

52W High$79.08572

52W Low$53.88572

Avg Volume188K

Open$62.40

Beta0.48

Free Cash Flow Financials Revenue

Middle East Pharmaceutical Industries Company (4016.SR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

4016.SR · free cash flow · updated Jun 15, 2026

Core FCF metrics

4016.SR · FCF · TTM · margin & CAGR

Free cash flow was $78.3M for FY2025 (fiscal year ending 2025-12-31), up 224.6% year-over-year The FCF margin was 17.0%. Five-year CAGR stands at +74.5%.

FY2025 Free Cash Flow$78.3M▲ +224.6% YoY

Trailing 12M (TTM)$49.8Mtrailing 4 quarters sum

FCF Margin17.0%$78.3M ÷ revenue

3-Year CAGR+21.2%FY2022 → FY2025

5-Year CAGR+74.5%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

4016.SR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$93.1M(15M)$78.3M▲ +224.6%17.0%

FY2024$35.3M(11M)$24.1M▼ 66.4%6.1%

FY2023$92.7M(21M)$71.8M▲ +63.1%21.2%

FY2022$64.6M(21M)$44.0M▲ +174.5%14.6%

FY2021$40.7M(25M)$16.0M▲ +231.2%5.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

4016.SR · P/FCF · FCF yield · FCF per share

Middle East Pharmaceutical Industries Company (4016.SR) trades at a FCF yield of 2.29% and a price-to-free-cash-flow ratio of 43.7x. FCF per share stands at $1.42, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

2.29%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.42

TTM FCF ÷ Shares Outstanding

Price / FCF

x43.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x44.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

4016.SR · cash flow statement · operating / investing / financing

For FY2025, Middle East Pharmaceutical Industries Company generated $93.1M in operating cash flow and spent 15M in capital expenditures, yielding $78.3M in free cash flow.

Operating Activities

+$93.1M

Cash from core business operations

2025-12-31

Investing Activities

−$34.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$47.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($93.1M) − |CapEx| (15M) = FCF ($78.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

4016.SR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Middle East Pharmaceutical Industries CompanyYOU

4016.SR

$78.3M+224.6%17.0%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Middle East Pharmaceutical Industries Company (4016.SR) reported free cash flow of $78.3M for FY2025 (fiscal year ending 2025-12-31), up 224.6% year-over-year. The FCF margin was 17.0%.

Based on available data, Middle East Pharmaceutical Industries Company has maintained positive free cash flow for at least 7 fiscal year(s). FCF peaked at $78.3M in FY2025. The 5-year CAGR stands at +74.5%.

Middle East Pharmaceutical Industries Company's FCF yield is 2.29% and price-to-FCF ratio is 43.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

4016.SR free cash flow · 8 questions

Middle East Pharmaceutical Industries Company free cash flow was $78.3M for FY2025, up 224.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $49.8M.

4016.SR free cash flow4016.SR FCF4016.SR FCF 20254016.SR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Middle East Pharmaceutical Industries Company · Middle East Pharmaceutical Industries Company SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026